Analyst PT cut
Beam is falling violently as growth and biotech stocks sell off, with a small Canaccord Genuity price-target cut adding pressure even as Jones Trading starts coverage with a buy.
Sources: https://www.investing.com/news/analyst-ratings/5003372, https://www.biospectrumasia.com/index.php/news/50/13592/beam-therapeutics-bio-palette-to-develop-microbiome-related
Previous verdicts for BEAM
- AI Search: Beam Therapeutics Slips Modestly Despite Positive Risto-cel Pivotal Data — 2026-11-10
- BEAM sharply up — 2026-11-04
- AI Search: Beam Therapeutics Rises Modestly on Bullish BEAM-301 Clinical Data — 2026-10-28
- AI Search: Beam Therapeutics Rallies Sharply on BEAM-301 Clinical Data — 2026-10-27
- AI Search: BEAM Climbs Modestly on Mixed News and No Clear Catalyst — 2026-10-19
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works